Serum Anti-CCNY Autoantibody Is an Independent Prognosis Indicator for Postoperative Patients with Early-Stage Nonsmall-Cell Lung Carcinoma

Table 2

Multivariate analysis of prognostic factors in patients with NSLCL.

Covariate	Covariate subgroup	HR	95% CI	𝑃
Age	≤60	1.127	0.557–2.281	0.739
	>60
Gender	Male	1.705	0.353–8.241	0.323
	Female
Smoke	Yes	0.189	0.013–2.713	0.220
	No
Smoke index	≤400	0.485	0.219–1.072	0.740
	>400
Tumor site	Right	1.522	0.712–3.251	0.278
	Left
Pathology type	A	0.565	0.236–1.352	0.200
	S
Differentiation	Poor	0.616	0.304–1.248	0.179
	Moderate + well
Levels of CCNY antibody	Negative	4.044	1.849–8.843	0.006
	Positive
T	T1	1.290	0.838–1.981	0.247
	T2, 3, 4
N	N0	1.121	0.763–1.645	0.561
	N1, 2, 3
M	M0	4.485	1.412–14.243	0.011
	M1
Levels of CCNY antibody	Negative	2.380	1.101–5.104	0.026
	Positive
M	M0	4.092	1.371–12.210	0.012
	M1

𝑃: 𝑃 value; RR: relative risk to relapse; CI: confidence interval. Define 𝑃<0.05 as the significant difference.